Value of three-dimensional power Doppler to predict clinical and histological response to neoadjuvant chemotherapy in locally advanced cervical carcinoma

Ultrasound in Obstetrics and Gynecology

Volumn 39, Issue 2, 2012, Pages 226-234

  Qin, J ^a   Cheng, X ^a   Chen, X ^a   Zhang, X ^a   Lu, W ^a   Xie, X ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

3D power Doppler vascular indices; clinical response; FI; flow index; histological response

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; DOPPLER FLOWMETRY; ECHOGRAPHY; FEMALE; HUMAN; HYSTERECTOMY; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; SQUAMOUS CELL CARCINOMA; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; HYSTERECTOMY; IMAGING, THREE-DIMENSIONAL; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84856325591     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.10071     Document Type: Review

References (35)

1. Sardi J, Sananes C, Giaroli A, Bayo J, Rueda NG, Vighi S, Guardado N, Paniceres G, Snaidas L, Vico C, Paola G,. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix. Gynecol Oncol 1993; 49: 156-165. (Pubitemid 23169984)
2. Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C, Landoni F,. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 2002; 20: 179-188. (Pubitemid 34032610)
3. Benedetti-Panici P, Greggi S, Scambia G, Amoroso M, Salerno MG, Maneschi F, Cutillo G, Paratore MP, Scorpiglione N, Mancuso S,. Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Eur J Cancer 1998; 34: 341-346. (Pubitemid 28183831)
4. Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, Chiari S, Buda A, Landoni F, Peiretti M, Dell'anna T, Fruscio R, Signorelli M, Grassi R, Floriani I, Fossati R, Torri V, Rulli E,. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study. Ann Oncol 2009; 20: 660-665.
5. Neoadjuvant chemotherapy for locally advanced cervix cancer. Cochrane Database Syst Rev 2004; CD001774.
6. Kornovski Y, Gorchev G,. Neoadjuvant chemotherapy followed by radical surgery and radiotherapy vs. pelvic irradiation in patients with cervical cancer FIGO stage IIB-IVA. J BUON 2006; 11: 291-297. (Pubitemid 44756020)
7. Lai CH, Hsueh S, Chang TC, Tseng CJ, Huang KG, Chou HH, Chen SM, Chang MF, Shum HC,. Prognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy. Gynecol Oncol 1997; 64: 456-462. (Pubitemid 27120436)
8. Loizzi V, Cormio G, Vicino M, Selvaggi L,. Neoadjuvant chemotherapy: an alternative option of treatment for locally advanced cervical cancer. Gynecol Obstet Invest 2008; 65: 96-103. (Pubitemid 351341521)
9. Cheng XD, Lu WG, Ye F, Wan XY, Xie X,. The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. J Exp Clin Cancer Res 2009; 28: 91.
10. Hoogsteen IJ, Marres HA, van der Kogel AJ, Kaanders JH,. The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. Clin Oncol (R Coll Radiol) 2007; 19: 385-396. (Pubitemid 47007426)
11. Menon C, Fraker DL,. Tumor oxygenation status as a prognostic marker. Cancer Lett 2005; 221: 225-235. (Pubitemid 40460409)
12. Milosevic M, Fyles A, Hedley D, Hill R,. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 2004; 14: 249-258. (Pubitemid 38903229)
13. O'Connor JP, Naish JH, Parker GJ, Waterton JC, Watson Y, Jayson GC, Buonaccorsi GA, Cheung S, Buckley DL, McGrath DM, West CM, Davidson SE, Roberts C, Mills SJ, Mitchell CL, Hope L, Ton NC, Jackson A,. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys 2009; 75: 1209-1215.
14. Gallez B,. [Development of new methods of magnetic resonance for the characterization of oxygenation and perfusion of tumors. Diagnostic and therapeutic applications]. Bull Mem Acad R Med Belg 2007; 162: 323-330.
15. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J,. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 2003; 47: 8-13. (Pubitemid 36826756)
16. Padhani AR,. Functional MRI for anticancer therapy assessment. Eur J Cancer 2002; 38: 2116-2127. (Pubitemid 35223249)
17. Krishna MC, English S, Yamada K, Yoo J, Murugesan R, Devasahayam N, Cook JA, Golman K, Ardenkjaer-Larsen JH, Subramanian S, Mitchell JB,. Overhauser enhanced magnetic resonance imaging for tumor oximetry: coregistration of tumor anatomy and tissue oxygen concentration. Proc Natl Acad Sci USA 2002; 99: 2216-2221. (Pubitemid 34169041)
18. Isa AY, Ward TH, West CM, Slevin NJ, Homer JJ,. Hypoxia in head and neck cancer. Br J Radiol 2006; 79: 791-798. (Pubitemid 44613678)
19. Williams KJ, Parker CA, Stratford IJ,. Exogenous and endogenous markers of tumour oxygenation status: definitive markers of tumour hypoxia? Adv Exp Med Biol 2005; 566: 285-294. (Pubitemid 43779514)
20. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA,. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008; 51: 1641-1648.
21. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A,. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997; 38: 1155-1160. (Pubitemid 27339632)
22. Raine-Fenning NJ, Nordin NM, Ramnarine KV, Campbell BK, Clewes JS, Perkins A, Johnson IR,. Evaluation of the effect of machine settings on quantitative three-dimensional power Doppler angiography: an in-vitro flow phantom experiment. Ultrasound Obstet Gynecol 2008; 32: 551-559.
23. th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (Suppl. 1): S43-S103.
24. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication. WHO: Geneva, 1979.
25. Japan Society for Cancer Therapy: Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 1993; 28: 101-130.
26. Alcazar JL, Castillo G, Martinez-Monge R, Jurado M,. Transvaginal color Doppler sonography for predicting response to concurrent chemoradiotherapy for locally advanced cervical carcinoma. J Clin Ultrasound 2004; 32: 267-272. (Pubitemid 38857139)
27. Testa AC, Ferrandina G, Distefano M, Fruscella E, Mansueto D, Basso D, Salutari V, Scambia G,. Color Doppler velocimetry and three-dimensional color power angiography of cervical carcinoma. Ultrasound Obstet Gynecol 2004; 24: 445-452. (Pubitemid 39179483)
28. Qin J, Wang J, Lu W, Li Y, Yao W, Qian Y,. Comparison of reproducibility of manual and sphere contour methods for the measurement of vascularization in cervical carcinoma using the virtual organ computer-aided analysis II system. J Ultrasound Med 2010; 29: 1801-1810.
29. Feldmann HJ,. Oxygenation of human tumors-implications for combined therapy. Lung Cancer 2001; 33 (Suppl. 1): S77-S83. (Pubitemid 32884358)
30. Hockel M, Vaupel P,. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-276. (Pubitemid 32219813)
31. Eisenhauer EA, Vermorken JB, van Glabbeke M,. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]. Ann Oncol 1997; 8: 963-968. (Pubitemid 27475726)
32. Green SL, Giaccia AJ,. Tumor hypoxia and the cell cycle: implications for malignant progression and response to therapy. Cancer J Sci Am 1998; 4: 218-223.
33. Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Bertoli G, Alquati P, Dogliotti L,. Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer. Br J Cancer 2003; 89: 977-982. (Pubitemid 37239198)
34. Hastie T, Tibshirani R, Friedman J,. The Elements of Statistical Learning: Data mining, Inference and Prediction. Springer: New York, 2009.
35. Brown JM, Giaccia AJ,. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Research 1998; 58: 1408-1416. (Pubitemid 28193601)